https://www.selleckchem.com/pr....oducts/eflornithine-
0% to 69.8%, higher than FIT (21.9%), but at the expense of specificities (51.6% to 78.3% vs 97.1%). For population having ACN prevalence of 3%, risk-adapted screening strategies needed 20.5 to 31.1 additional false positives for each additional true positive compared with FIT, and respective number would substantially reduce (4.7 to 7.1) as the ACN prevalence increased to 12%. Risk-adapted screening strategy using the current risk models showed improved sensitivity for ACN compared with FIT, at the cost of in
Like
Comment
Share
